Sedana Medical AB (SEDANA) AI Stock Analysis

• Market Cap: kr1.21B
• Dividend Yield: N/A
• Average Volume (3M): 272.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 13.66%
• EPS Growth: -139.90%
• Country: SE
• Employees: 113
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.24
• Shares Outstanding: 99,336,960
• 10 Day Avg. Volume: 157,353
• 30 Day Avg. Volume: 272,630
• PEG Ratio: -1.93
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: kr12.50 ▲(2.97%Upside)

Sedana Medical demonstrates strong revenue growth and financial stability with a low debt-to-equity ratio. However, significant challenges persist with negative profitability and cash flow issues. Technical indicators suggest moderate bullish momentum, but valuation concerns due to negative earnings impact the overall attractiveness.

Sedana Medical AB Business Overview & Revenue Model

Company Description

Sedana Medical AB (SEDANA) is a Swedish medical technology company that specializes in developing, marketing, and selling medical devices and pharmaceuticals for inhalation sedation. Sedana Medical's core product is the AnaConDa, a system designed to administer volatile anesthetics for sedation in intensive care units. The company operates primarily within the healthcare sector, focusing on providing innovative solutions to improve patient care and outcomes in critical care settings.

How the Company Makes Money

Sedana Medical makes money primarily through the sales of its AnaConDa system and related consumables. The AnaConDa system is sold to hospitals and healthcare facilities, where it is used for sedating patients in intensive care units. Revenue is generated from both the initial sale of the AnaConDa device and the recurring sales of consumables required for its operation. Sedana Medical may also generate revenue through partnerships and collaborations with healthcare providers and distributors, as well as through potential licensing agreements for its technology.

Sedana Medical AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
178.75M	153.87M	122.86M	159.15M	141.77M
	Gross Profit
126.14M	108.98M	86.07M	106.71M	88.90M
	EBIT
-50.77M	-65.55M	-103.93M	-61.20M	-21.54M
	EBITDA
-29.17M	-51.67M	-64.87M	-49.10M	-17.22M
	Net Income Common Stockholders
-10.67M	-59.61M	-73.51M	-57.97M	-27.14M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
193.96M	381.80M	607.74M	836.18M	376.17M
	Total Assets
1.02B	1.01B	1.08B	1.17B	600.10M
	Total Debt
5.92M	4.31M	8.74M	8.87M	8.29M
	Net Debt
-188.04M	-226.87M	-599.00M	-827.31M	-367.88M
	Total Liabilities
61.17M	44.06M	52.43M	66.12M	49.00M
	Stockholders Equity
958.26M	970.00M	1.03B	1.10B	551.09M
Cash Flow		Free Cash Flow
-186.77M	-206.95M	-253.22M	-151.48M	-92.47M
	Operating Cash Flow
-11.77M	-38.06M	-115.43M	-41.22M	-7.85M
	Investing Cash Flow
-44.67M	-321.96M	-137.78M	-110.25M	-84.62M
	Financing Cash Flow
-3.57M	-4.86M	-1.51M	605.07M	5.79M

Sedana Medical AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.14
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Negative. The current price of 12.14 is below the 20-day moving average (MA) of 12.80, above the 50-day MA of 10.61, and below the 200-day MA of 16.06, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 50.62 is Neutral, neither overbought nor oversold. The STOCH value of 35.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEDANA.

Sedana Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	kr1.15B	35.49	10.11%	―	2.53%	-44.90%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
INTEG.B	53 Neutral	€430.95M	―	-19.17%	―	-12.50%	-783.92%
SEDANA	52 Neutral	kr1.21B	―	-5.61%	―	13.66%	-139.90%
MNTC	49 Neutral	kr531.83M	―	-17.16%	―	17.75%	18.05%
ACARIX	46 Neutral	€255.30M	―	-88.97%	―	-0.61%	54.19%
BACTI.B	46 Neutral	kr1.05B	―	-7.30%	―	23.51%	80.47%

Sedana Medical AB Corporate Events

Sedana Medical AB Annual General Meeting Highlights Key Resolutions

Sedana Medical AB held its annual general meeting on May 15, 2025, where key resolutions were passed, including the adoption of financial statements for 2024 and the decision not to distribute dividends. The meeting also approved the re-election of board members and auditors, and authorized the board to issue new shares. A performance-based incentive program for employees was introduced, aimed at aligning staff interests with company growth, potentially impacting employee motivation and shareholder value.

Sedana Medical Reports Record Quarter with Strong Sales Growth

Sedana Medical AB reported a record quarter with net sales increasing by 18% compared to the same period in 2024, driven by its focus on inhaled sedation products. Despite facing negative currency effects, the company showed improved financial performance with a reduced EBITDA loss and positive cash flow from operating activities, highlighting its strong market positioning and operational resilience.